KDR and nasopharyngeal carcinoma: A multikinase inhibitor called famitinib which targets stem cell growth factor receptor Kit (KIT), platelet-derived growth factor receptor (PDGFR), and VEGFR was tested in patients with recurrent and/or metastatic NPC after failing more than two previous treatment regimens [37].